

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**CHANGE OF JOINT COMPANY SECRETARY
AND
WAIVER FROM STRICT COMPLIANCE
WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

RESIGNATION OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Ms. Jin Jin (金今) (“**Ms. Jin**”) has resigned as a joint company secretary of the Company (the “**Joint Company Secretary**”) for personal development reasons with effect from 6 February 2026.

Ms. Jin has confirmed that she has no disagreements with the Board and there is no matter in relation to her resignation that should be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company (the “**Shareholders**”). The Board is also not aware of other matters that need to be brought to the attention of the Shareholders and the Stock Exchange in connection with her resignation.

The Board would like to take this opportunity to express its gratitude for Ms. Jin’s valuable contribution to the Company during her tenure of office.

APPOINTMENT OF JOINT COMPANY SECRETARY

The Board is pleased to announce that Ms. Yang Dongyan (楊東妍) (“**Ms. Yang**”) has been appointed as a Joint Company Secretary with effect from 6 February 2026. Ms. Yang will jointly perform the duties of company secretary with Ms. Sze Suet Ling (施雪玲) (“**Ms. Sze**”), who is currently the other Joint Company Secretary.

The biographical details of Ms. Yang are set out as follows:

Ms. Yang Dongyan (楊東妍), aged 40, obtained a bachelor's degree in law from the East China University of Political Science and Law (華東政法大學) in 2008 and holds a Legal Professional Qualification Certificate (《法律職業資格證書》). Between August 2008 and April 2021, Ms. Yang held various roles at Shanghai Wyselead Law Firm (上海市匯理律師事務所), including as a lawyer between March 2011 and November 2020 and a partner between November 2020 and April 2021. Since April 2021, Ms. Yang has served as the legal director of the Group.

The biographical details of Ms. Sze are set out as follows:

Ms. Sze Suet Ling (施雪玲), aged 41, was appointed as a Joint Company Secretary in October 2024. She currently serves as an assistant vice president of SWCS Corporate Services Group (Hong Kong) Limited.

Ms. Sze has over 15 years of experience in corporate governance and company secretarial practice in listed companies on the Main Board of the Stock Exchange. Ms. Sze is a Chartered Secretary, a Chartered Governance Professional, and an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. She is also a full-member of Hong Kong Investor Relations Association.

Ms. Sze obtained a bachelor's degree in business administration and management from the University of Huddersfield in November 2007 in the United Kingdom and a master's degree in corporate governance from The Open University of Hong Kong (currently known as Hong Kong Metropolitan University) in June 2014.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), a listed issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary.

Notwithstanding that Ms. Yang currently does not possess the academic or professional qualifications required under Note 1 to Rule 3.28 of the Listing Rules, taking into account (i) Ms. Yang's legal knowledge and background; (ii) her familiarity with the daily operation and business of the Group; and (iii) her previous assistance to Ms. Jin with company secretarial matters, the Company considers that Ms. Yang is a suitable person to act as a Joint Company Secretary by virtue of her background, experience and familiarity with the Group.

Ms. Sze will continue to be the other Joint Company Secretary. Ms. Sze possesses all the requisite qualifications under Rule 3.28 of the Listing Rules, and will ensure that she will be available at all times to assist Ms. Yang in discharging her duties as a Joint Company Secretary and in gaining the "relevant experience" as required under Note 2 to Rule 3.28 of the Listing Rules.

On the basis of the foregoing, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) for the a period of three years from 6 February 2026 (the “**Waiver Period**”), i.e., from the date of appointment of Ms. Yang as a Joint Company Secretary, on the following conditions:

- (a) Ms. Yang must be assisted by Ms. Sze during the Waiver Period; and
- (b) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms. Yang, having had the benefit of Ms. Sze’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

The Board would like to take this opportunity to warmly welcome Ms. Yang on her appointment.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People’s Republic of China, 6 February 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.